Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials - Summary - MDSpire

Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials

  • By

  • Shuo Zhao

  • Miaoqin Wu

  • Jingxiang Zhong

  • Baihua Chen

  • Zongming Song

  • Zhang Ming

  • Quanhong Han

  • Suqin Yu

  • Hong Wang

  • Songtao Yuan

  • Jin Yao

  • Mingwei Zhao

  • Xiaohong Meng

  • Feng Wang

  • Jing Lou

  • Yanli Liu

  • Haomin Huang

  • Qinghong Zhou

  • Yuyu Xu

  • Hong Dai

  • Xiaorong Li

  • July 1, 2026

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of monoclonal antibody 601 compared to ranibizumab in patients with macular oedema secondary to retinal vein occlusion (RVO).

Approach:
    Key Findings:
    • 601 provided robust and similar vision and anatomic improvement to ranibizumab throughout 52 weeks.
    • Both treatments demonstrated a favourable safety profile.
    Interpretation:

    The results indicate that 601 is a promising option for managing RVO-related macular oedema.

    Limitations:
    • The study was limited to a small sample size of 60 patients per trial.
    • The exploratory nature of phase II trials may affect the generalizability of results.
    Conclusion:

    601 shows comparable efficacy and safety to ranibizumab in treating macular oedema associated with RVO.

Original Source(s)

Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials

  • by Shuo Zhao, Miaoqin Wu, Jingxiang Zhong, Baihua Chen, Zongming Song, Zhang Ming, Quanhong Han, Suqin Yu, Hong Wang, Songtao Yuan, Jin Yao, Mingwei Zhao, Xiaohong Meng, Feng Wang, Jing Lou, Yanli Liu, Haomin Huang, Qinghong Zhou, Yuyu Xu, Hong Dai, Xiaorong Li

  • July 1, 2026

Related Content

Vitreoretinal Surgery at High Altitude

Elevation affects vitrectomy fluidics, intraocular gas behavior, tamponade selection, and postoperative travel planning.

From Roomba to Robotic Surgery

The promise of robotic cataract surgery has been floating through the halls of ophthalmology meetings for years, and it appears the promise is now on its way to reality.

Surgical Roundtable Case 1: Managing Giant Retinal Tears

Mrinali Gupta, MD, FASRS, demonstrates surgical repair of a traumatic giant retinal tear (GRT) detachment in a 50-year-old phakic patient, and a panel of experienced vitreoretinal surgeons discusses approaches to scleral buckling, tamponade selection, laser retinopexy, and techniques to prevent slippage.